EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Analysis of particle therapy registries based on a unified treatment policy for esophageal cancer

Sunao Tokumaru, Hitoshi Ishikawa, Toshinori Soejima, Takuya Kimoto, Yosuke Takakusagi, Hiroyasu Tamamura, Hitoshi Wada, Hiroshi Taguchi, Yusuke Uchinami, Yuichi Hiroshima, Hidehiro Hojo, Takashi Kamei und 2 weitere

Journal of Radiation Research · 2023

DOI: 10.1093/jrr/rrad012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Radiation Research, 2023. Verfasst von Sunao Tokumaru und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Hyogo Ion Beam Medical Center, 1-2-1 Kouto, Shingu-cho, Tatsuno, Hyogo 679-5165, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Proton Therapy, Esophageal Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institutes for Quantum and Radiological Science and Technology Library, J-CROS (Japan Carbon-Ion Radiation Oncology Study Group), Proton-Net (Japanese proton beam therapy network).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to evaluate the efficacy and safety of particle therapy (proton beam therapy and carbon-ion radiotherapy) for esophageal cancer by analyzing prospective nationwide registry data from particle therapy facilities throughout Japan. Patients diagnosed with esophageal cancer who received particle therapy between May 2016 and June 2018 were recruited from the registries of 12 particle therapy centers in Japan. Eventually, we enrolled 174 patients who met the inclusion criteria. Of the 174 patients, 137 (78.7%) were male, with a median age of 69 years (range: 41–88 years). Clinical stages included I (n = 55; 31.6%), II (n = 31; 17.8%), III (n = 82; 47.1%), IV (n = 3; 1.7%) and unknown (n = 3; 1.7%) (Union for International Cancer Control, seventh edition), and the median follow-up period was 908 days (range: 76–1669 days) for all patients. The 3-year overall survival (OS) rate, the 3-year progression-free survival (PFS) rate and the 3-year local control (LC) rates were 60.5, 53.2 and 72.7%, respectively. For each clinical stage, the 3-year OS rates were I, 84.8%; II, 60.3% and III, 42.9%; the 3-year PFS rates were I, 71.9%; II, 58.3% and III, 37.0% and the 3-year LC were I, 78.4%; II, 79.8% and III, 65.2%, respectively. Notably, four patients (2.3%) with ≥Grade 3 cardiopulmonary toxicities were observed (Common Terminology Criteria for Adverse Events, version 5.0). Our study showed that particle therapy for esophageal cancer has lower rates of adverse cardiopulmonary events than X-ray radiotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungProton TherapyEsophageal NeoplasmsLung NeoplasmsHumansMaleAdultMiddle AgedAgedAged, 80 and overFemaleProspective Studies

Stichwörter der Autor:innen

esophageal canceroutcomeparticle therapytoxicity

Autor:innen und Institutionen

  • Department of Radiology, Hyogo Ion Beam Medical Center, 1-2-1 Kouto, Shingu-cho, Tatsuno, Hyogo 679-5165, Japan.
  • National Institutes for Quantum and Radiological Science and Technology, QST Hospital, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.
  • Department of Radiation Oncology, Hyogo Ion Beam Medical Center Kobe Proton Center, 1-6-8 Minatojima Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan.
  • Department of Radiology, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.
  • Department of Radiation Oncology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515, Japan.
  • Proton Therapy Center, Fukui Prefectural Hospital, 2-8-1, Yotsui, Fukui, Fukui 910-8526, Japan.

Förderung

  • National Institutes for Quantum and Radiological Science and Technology Library
  • J-CROS (Japan Carbon-Ion Radiation Oncology Study Group)
  • Proton-Net (Japanese proton beam therapy network)

Zitieren

APA

Tokumaru, S., Ishikawa, H., Soejima, T., Kimoto, T., Takakusagi, Y., Tamamura, H., Wada, H., Taguchi, H., Uchinami, Y., Hiroshima, Y., Hojo, H., Kamei, T., Muto, M., & Igeta, M. (2023). Analysis of particle therapy registries based on a unified treatment policy for esophageal cancer. Journal of Radiation Research. https://doi.org/10.1093/jrr/rrad012

Vancouver

Tokumaru S, Ishikawa H, Soejima T, Kimoto T, Takakusagi Y, Tamamura H, et al. Analysis of particle therapy registries based on a unified treatment policy for esophageal cancer. Journal of Radiation Research. 2023. doi:10.1093/jrr/rrad012

BibTeX
@article{Tokumaru2023,
  author = {Tokumaru, Sunao and Ishikawa, Hitoshi and Soejima, Toshinori and Kimoto, Takuya and Takakusagi, Yosuke and Tamamura, Hiroyasu and Wada, Hitoshi and Taguchi, Hiroshi and Uchinami, Yusuke and Hiroshima, Yuichi and Hojo, Hidehiro and Kamei, Takashi and Muto, Manabu and Igeta, Masataka},
  title = {Analysis of particle therapy registries based on a unified treatment policy for esophageal cancer},
  journal = {Journal of Radiation Research},
  year = {2023},
  doi = {10.1093/jrr/rrad012}
}
Kostenlos starten →